Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ta-8995
1. Ta-8995
2. 866399-87-3
3. Obicetrapib (free Base)
4. Amg-899
5. Dez-001
6. Obicetrapib [inn]
7. 8o74k609hn
8. 866399-87-3 (free Base)
9. (2r,4s)-4-((3,5-bis(trifluoromethyl)benzyl)(5-(3-carboxypropoxy)pyrimidin-2-yl)amino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2h-quinoline-1-carboxylic Acid Ethyl Ester
10. 1(2h)-quinolinecarboxylic Acid, 4-(((3,5-bis(trifluoromethyl)phenyl)methyl)(5-(3-carboxypropoxy)-2-pyrimidinyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, 1-ethyl Ester, (2r,4s)-
11. 1-ethyl (2r,4s)-4-[[[3,5-bis(trifluoromethyl)phenyl]methyl][5-(3-carboxypropoxy)-2-pyrimidinyl]amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-1(2h)-quinolinecarboxylate
12. 4-((2-(((3,5-bis(trifluoromethyl)phenyl)methyl)((2r,4s)-1- (ethoxycarbonyl)-2-ethyl-6-(trifluoromethyl)-1,2,3,4- Tetrahydroquinolin-4-yl)amino)pyrimidin-5-yl)oxy)butanoic Acid
13. 4-((2-((3,5-bis(trifluoromethyl)benzyl)((2r,4s)-1-(ethoxycarbonyl)-2-ethyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl)amino)pyrimidin-5-yl)oxy)butanoic Acid
14. 4-[2-[[3,5-bis(trifluoromethyl)phenyl]methyl-[(2r,4s)-1-ethoxycarbonyl-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinolin-4-yl]amino]pyrimidin-5-yl]oxybutanoic Acid
15. Obicetrapib [who-dd]
16. Unii-8o74k609hn
17. Chembl3785197
18. Schembl17002081
19. Gtpl12205
20. Ex-a6112
21. Ta8995
22. Obicetrapib (amg-899,ta-8995)
23. Db14890
24. Ac-35552
25. Hy-18778
26. Q27270811
| Molecular Weight | 722.6 g/mol |
|---|---|
| Molecular Formula | C32H31F9N4O5 |
| XLogP3 | 7.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 17 |
| Rotatable Bond Count | 12 |
| Exact Mass | 722.21507356 g/mol |
| Monoisotopic Mass | 722.21507356 g/mol |
| Topological Polar Surface Area | 105 Ų |
| Heavy Atom Count | 50 |
| Formal Charge | 0 |
| Complexity | 1100 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
9.1k
<10
25.0
2,27,250.4
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|---|---|---|
| INDIA | 25.03 | 9,079.1 | <10 |
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Lead Product(s): Obicetrapib,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: NewAmsterdam Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2024
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : NewAmsterdam Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Menarini’s Obicetrapib Trials Show Positive Phase 3 Data for Cholesterol Reduction
Details : TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Product Name : TA-8995
Product Type : Small molecule
Upfront Cash : Not Applicable
December 16, 2024
Details:
The net proceeds will be to advance the clinical development of TA-8995 (obicetrapib), which is being evaluated in the late-stage trial studies for the treatment of Atherosclerosis.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Jefferies
Deal Size: $452.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 13, 2024
Lead Product(s) : Obicetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jefferies
Deal Size : $452.6 million
Deal Type : Public Offering
NewAmsterdam Closes $479M Upsized Offering With Full Exercise Of Underwriters’ Option
Details : The net proceeds will be to advance the clinical development of TA-8995 (obicetrapib), which is being evaluated in the late-stage trial studies for the treatment of Atherosclerosis.
Product Name : TA-8995
Product Type : Small molecule
Upfront Cash : Undisclosed
December 13, 2024
Details:
The net proceeds will be to advance the clinical development of TA-8995 (obicetrapib), which is being evaluated in the late-stage trial studies for the treatment of Atherosclerosis.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Jefferies
Deal Size: $416.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 11, 2024
Lead Product(s) : Obicetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jefferies
Deal Size : $416.5 million
Deal Type : Public Offering
NewAmsterdam Prices $416.5 Million Upsized Offering Of Shares And Pre-Funded Warrants
Details : The net proceeds will be to advance the clinical development of TA-8995 (obicetrapib), which is being evaluated in the late-stage trial studies for the treatment of Atherosclerosis.
Product Name : TA-8995
Product Type : Small molecule
Upfront Cash : Undisclosed
December 11, 2024
Details:
The net proceeds will be to advance the clinical development of TA-8995 (obicetrapib), which is being evaluated in the late-stage trial studies for the treatment of Atherosclerosis.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Jefferies
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 10, 2024
Lead Product(s) : Obicetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jefferies
Deal Size : $300.0 million
Deal Type : Public Offering
NewAmsterdam Pharma Begins $300 Million Offering Of Shares And Pre-Funded Warrants
Details : The net proceeds will be to advance the clinical development of TA-8995 (obicetrapib), which is being evaluated in the late-stage trial studies for the treatment of Atherosclerosis.
Product Name : TA-8995
Product Type : Small molecule
Upfront Cash : Undisclosed
December 10, 2024
Details:
TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Lead Product(s): Obicetrapib,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2024
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NewAmsterdam Pharma Announces Phase 3 BROADWAY Trial Data for Obicetrapib
Details : TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 10, 2024
Details:
TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Lead Product(s): Obicetrapib,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2024
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NewAmsterdam Releases Phase 3 TANDEM Data for Obicetrapib-Ezetimibe in ASCVD Patients
Details : TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Product Name : TA-8995
Product Type : Small molecule
Upfront Cash : Not Applicable
November 20, 2024
Details:
TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor. It is currently being investigated in adult patients with Heterozygous Familial Hypercholesterolemia.
Lead Product(s): Obicetrapib
Therapeutic Area: Genetic Disease Brand Name: TA-8995
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: NewAmsterdam Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2024
Lead Product(s) : Obicetrapib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : NewAmsterdam Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
NewAmsterdam Pharma to Announce Phase 3 Data for Obicetrapib in Hypercholesterolemia
Details : TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor. It is currently being investigated in adult patients with Heterozygous Familial Hypercholesterolemia.
Product Name : TA-8995
Product Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2024
Details:
TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Lead Product(s): Obicetrapib,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2024
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NewAmsterdam Pharma Completes Enrollment in Phase 3 TANDEM Trial for Obicetrapib
Details : TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe, is being evaluated for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Product Name : TA-8995
Product Type : Small molecule
Upfront Cash : Not Applicable
July 08, 2024
Details:
TA-8995 (obicetrapib), a next-generation, non statin, oral once-daily, low-dose CETP inhibitor. Currently being investigated in adult patients with a history of atherosclerotic cardiovascular disease.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Lead Product(s) : Obicetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NewAmsterdam Enrolls 9K+ in Phase 3 Trial of Obicetrapib for Cardiovascular Disease
Details : TA-8995 (obicetrapib), a next-generation, non statin, oral once-daily, low-dose CETP inhibitor. Currently being investigated in adult patients with a history of atherosclerotic cardiovascular disease.
Product Name : TA-8995
Product Type : Small molecule
Upfront Cash : Not Applicable
April 09, 2024
Details:
NewAmsterdam TA-8995 (obicetrapib) is a CETP inhibitor combined with Ezetimibe, under evaluation in Phase III trials for Heterozygous Familial Hypercholesterolemia and cardiovascular disease.
Lead Product(s): Obicetrapib,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TA-8995
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NewAmsterdam Doses First Patient in Phase 3 TANDEM Trial for Obicetrapib
Details : NewAmsterdam TA-8995 (obicetrapib) is a CETP inhibitor combined with Ezetimibe, under evaluation in Phase III trials for Heterozygous Familial Hypercholesterolemia and cardiovascular disease.
Product Name : TA-8995
Product Type : Small molecule
Upfront Cash : Not Applicable
March 12, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
31
PharmaCompass offers a list of Obicetrapib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Obicetrapib manufacturer or Obicetrapib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Obicetrapib manufacturer or Obicetrapib supplier.
PharmaCompass also assists you with knowing the Obicetrapib API Price utilized in the formulation of products. Obicetrapib API Price is not always fixed or binding as the Obicetrapib Price is obtained through a variety of data sources. The Obicetrapib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Obicetrapib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Obicetrapib, including repackagers and relabelers. The FDA regulates Obicetrapib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Obicetrapib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Obicetrapib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Obicetrapib supplier is an individual or a company that provides Obicetrapib active pharmaceutical ingredient (API) or Obicetrapib finished formulations upon request. The Obicetrapib suppliers may include Obicetrapib API manufacturers, exporters, distributors and traders.
click here to find a list of Obicetrapib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Obicetrapib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Obicetrapib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Obicetrapib GMP manufacturer or Obicetrapib GMP API supplier for your needs.
A Obicetrapib CoA (Certificate of Analysis) is a formal document that attests to Obicetrapib's compliance with Obicetrapib specifications and serves as a tool for batch-level quality control.
Obicetrapib CoA mostly includes findings from lab analyses of a specific batch. For each Obicetrapib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Obicetrapib may be tested according to a variety of international standards, such as European Pharmacopoeia (Obicetrapib EP), Obicetrapib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Obicetrapib USP).
